What Does Eyp Mean? the Story Behind Eyepoint's Duravyu Implant and Phase 3 Trial Results

Curious about What Does Eyp Mean? the Story Behind Eyepoint's Duravyu Implant and Phase 3 Trial Results? Uncover comprehensive breakdown in our full report.

Q1: What does EYP stand for in medical and stock news?
EYP refers to EyePoint Pharmaceuticals (traded under the ticker NASDAQ: EYPT) and its primary investigational drug candidate, EYP-1901 (known as DURAVYU).

Q2: Is EYP-1901 FDA approved yet?
As of late 2026, EYP-1901 is completing Phase 3 registration clinical trials for wet AMD and enrolling in Phase 3 trials for DME. EyePoint has not yet received final FDA commercial approval, but is assembling its New Drug Application (NDA) submissions based on primary non-inferiority endpoints.

Q3: How does receiving DURAVYU differ from a standard Eylea injection?
Both involve a brief, numbing in-office injection into the vitreous humor using an ultra-small needle. However, while Eylea or standard aflibercept injects a liquid that clears within weeks, DURAVYU places a tiny bioerodible solid polymer filament that continuously releases medication for six to nine months before fully dissolving on its own.

Q4: Why were the Phase 3 results described as "mixed"?
The trial successfully achieved its primary efficacy endpoint by proving that patients on EYP-1901 maintained visual acuity (BCVA) equal to those receiving standard aflibercept. However, secondary anatomical metrics, specifically clearing every trace of fluid on OCT scans, were less uniform, sparking clinical debate over anatomical versus functional success.